Galenica AG GALE.SW
Composite 46/100; the shares have moved about 15% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 33/100 — a moderate mark against it.
Income ranks 69/100 — a moderate point in its favour. Balance-sheet strength ranks 55/100 — a slight point in its favour. Growth ranks 51/100 — a slight point in its favour.
Momentum ranks 33/100 — a moderate mark against it. Valuation ranks 43/100 — a slight mark against it. Quality ranks 43/100 — a slight mark against it.
What the company does Galenica AG is a Swiss healthcare services provider operating pharmacies (Amavita, Sun Store, Coop Vitality), specialty pharmacy mediservice, home care, diagnostics, and logistics & IT solutions for pharmaceuticals and healthcare providers.
Key financials Galenica reports ROE 12.1%, ROA 4.5%, ROCE 18.7%, and net margin 4.4%. Revenue grew 5.8% while EPS fell -11.1%. Debt/Equity is 0.70 with interest coverage 17.30 and current ratio 1.15.
Stock health SideraVia scores Valuation 57.2 (51.9 overall), Income 77.9, and Momentum 42.8. Piotroski F-Score is 5/9 and Altman Z is 4.94, indicating moderate financial health.
Price vs fair value The stock trades at a PREMIUM of 21.10% to our fair-value estimate of 69.66 and a PREMIUM of 1.19% to the analyst 12-month target of 87.20. - Fwd P/E 20.79 vs trailing 23.95 (Valuation 57.2 percentile) - PEG 1.37 signals moderate growth valuation - Dividend yield 2.9% with payout 62.8% (Income 77.9) - 12-month EPS growth -11.1% (Growth 41.6)
Looking forward Forward P/E 20.79 and EV/EBITDA 12.64 suggest valuation is rich but not extreme. Momentum is mixed (12m 2.68%, 6m -6.61%), while profitability and income metrics remain supportive.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.